Snoring

Cranston Cosmetic Dentistry Announces New Website, Second Location

Retrieved on: 
星期一, 十二月 18, 2023
X-ray, Dentistry, Dental implant, Dental, Patient, Snoring, Cosmetic dentistry, Neoplasm, Bruxism, Root canal treatment, Dental care, Dentures, Diagnosis, TMJ

CRANSTON, R.I., Dec. 18, 2023 /PRNewswire-PRWeb/ -- Cranston Cosmetic Dentistry, a leading provider of cosmetic and family dentistry in the Cranston community, has launched a new website at https://www.cranstoncosmeticdentistry.com featuring patient testimonials, resources, and information about the latest in dental care. The company also recently announced the addition of a second location called Elite Dentistry of Rhode Island, which offers cosmetic dentistry to residents of East Greenwich and the surrounding areas.

Key Points: 
  • The company also recently announced the addition of a second location called Elite Dentistry of Rhode Island, which offers cosmetic dentistry to residents of East Greenwich and the surrounding areas.
  • CRANSTON, R.I., Dec. 18, 2023 /PRNewswire-PRWeb/ -- Cranston Cosmetic Dentistry, a leading provider of cosmetic and family dentistry in the Cranston community, has launched a new website at https://www.cranstoncosmeticdentistry.com featuring patient testimonials, resources, and information about the latest in dental care.
  • The company also recently announced the addition of a second location called Elite Dentistry of Rhode Island, which offers cosmetic dentistry to residents of East Greenwich and the surrounding areas.
  • Cranston Cosmetic Dentistry is led by Dr. Snehal Lakhar, a graduate of the Boston University Dental School and a specialist in cosmetic dentistry.

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
星期四, 十二月 7, 2023
Pressure, Nonsteroidal anti-inflammatory drug, Polyp (medicine), AstraZeneca, Inflammation, Face, Budesonide, Omalizumab, CRS, Eosinophilic granulomatosis with polyangiitis, Disease, Network congestion, PROPEL, Sleep apnea, Patient, Snoring, EU4, Sinusitis, Polyp, Allergic rhinitis, Fluticasone, Endoscopy, Smell, Nasal administration, Aspirin, Ibuprofen, Diagnosis, Cystic fibrosis, Tezepelumab, Risk, Growth, Glucocorticoid, Recurrence, Rhinorrhea, Mometasone, Physician, Asthma, LAS, Taste, GSK plc, Paranasal sinuses, Amgen, Pharmaceutical industry, Nursing

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
星期四, 十二月 7, 2023
Pressure, Nonsteroidal anti-inflammatory drug, Polyp (medicine), AstraZeneca, Inflammation, Face, Budesonide, Omalizumab, CRS, Eosinophilic granulomatosis with polyangiitis, Disease, Network congestion, PROPEL, Sleep apnea, Patient, Snoring, EU4, Sinusitis, Polyp, Allergic rhinitis, Fluticasone, Endoscopy, Smell, Nasal administration, Aspirin, Ibuprofen, Diagnosis, Cystic fibrosis, Tezepelumab, Risk, Growth, Glucocorticoid, Recurrence, Rhinorrhea, Mometasone, Physician, Asthma, LAS, Taste, GSK plc, Paranasal sinuses, Amgen, Pharmaceutical industry, Nursing

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

New Trends in Veterinary Medicine for 2024 Include Groundbreaking Treatments for America's Most Popular Pets: Cats, Frenchies and Bearded Dragons

Retrieved on: 
星期三, 十二月 6, 2023
Diet, World's fair, Pet, CAE, Texas A&M University, Cat, Reptile, The Show of Shows, Organization, Face, Hiatal hernia, Pneumonia, Diabetes, Tail, Disease, Risk, American Veterinary Medical Association, Mortality, Expo Hall, Patient, Diplomate of National Board, Frenchie, Veterinary medicine, Snoring, FDA, Animal, DVM, Humidity, MythBusters, University, Health, Veterinarian, Diagnosis, Learning, Doctor of Philosophy, Internal medicine, VMX, Dog, Education, Pharmaceutical industry, Animal husbandry

ORLANDO, Fla., Dec. 6, 2023 /PRNewswire/ -- Breakthrough drugs that can save the lives of thousands of diabetic cats, new approaches to help veterinarians and pet owners recognize and treat illnesses unique to French bulldogs, and how to better care for bearded dragons, America's most popular pet reptile, are just a sample of the more than 800 continuing education sessions that will be offered at the 41st annual Veterinary Meeting & Expo (VMX). Presented by the North American Veterinary Community (NAVC), VMX is the largest global veterinary conference and sets the direction each year for the $104 billion animal health industry. This forum for the latest advances and innovations in animal health will be held January 13 -17, 2024 in Orlando, Florida.

Key Points: 
  • This forum for the latest advances and innovations in animal health will be held January 13 -17, 2024 in Orlando, Florida.
  • "The global conference attracts the most distinguished veterinary leaders who will share and teach exciting breakthroughs taking place today across the industry.
  • VMX 2024 will look at new medications, many designed specifically for animals, and how technology is transforming how we diagnose and treat animals.
  • It's a very exciting and promising time to be in veterinary medicine."

ENT Laser Devices Market to grow by USD 119.6 million from 2022 to 2027; North America to account for 40% of market growth - Technavio

Retrieved on: 
星期四, 十一月 23, 2023
Tonsillitis, Nasal congestion, Prevalence, Boston Scientific, Sleep apnea, Head, ROW, Sinusitis, Soft tissue injury, Danaher Corporation, Research, FOX, AG, Snoring, USD, Rhinosinusitis, ENT, Free, Geography, ARC, GNS, Growth, Original equipment manufacturer, Smith, Gesellschaft mit beschränkter Haftung, Speciality chemicals, Cancer, Tinnitus

NEW YORK, Nov. 23, 2023 /PRNewswire/ -- The ENT laser devices market is expected to grow by USD 119.6 million from 2022 to 2027.

Key Points: 
  • NEW YORK, Nov. 23, 2023 /PRNewswire/ -- The ENT laser devices market is expected to grow by USD 119.6 million from 2022 to 2027.
  • The ENT devices market is estimated to grow by USD 8.83 billion at a CAGR of 6.34% between 2022 and 2027.
  • Detailed information on factors that will drive the growth of the ENT laser devices market between 2022 and 2027.
  • Growth of the ENT laser devices market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of ENT laser devices market companies.

Vivos Therapeutics Closes $4 Million Private Placement

Retrieved on: 
星期四, 十一月 2, 2023
Sale, OSA, Vivos, Snoring, Therapy, Patient, Security (finance)

LITTLETON, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced that today it has closed a $4 million private placement previously announced on October 31, 2023.

Key Points: 
  • LITTLETON, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, announced that today it has closed a $4 million private placement previously announced on October 31, 2023.
  • After deducting estimated offering expenses, Vivos expects the net proceeds from the private placement will be approximately $3.5 million.
  • In the private placement, Vivos issued to a single institutional investor 980,393 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.08 per share.
  • Additional details regarding the private placement will be provided in a Current Report on Form 8-K to be filed by Vivos with the U.S. Securities and Exchange Commission.

Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
星期二, 十月 31, 2023
Sale, OSA, Prospectus, Warrant (finance), Vivos, Snoring, Therapy, Patient, Security (finance)

The Series A and Series B Warrants will have an exercise price of $3.83 per share and will be exercisable immediately following the date of issuance.

Key Points: 
  • The Series A and Series B Warrants will have an exercise price of $3.83 per share and will be exercisable immediately following the date of issuance.
  • The closing of the private placement is expected to occur on or about November 2, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds from the offering are expected to be approximately $4.0 million.
  • Any offering of the securities under the resale registration statement will only be by means of a prospectus.

HelloFresh and Tinder Launch ‘Date Night Delights’ Recipe Series Helping New Couples Enter Their Forking Season

Retrieved on: 
星期一, 十一月 6, 2023
Specialty, Technology, Apps, Applications, Food, Beverage, Online Retail, Consumer, Other Consumer, Retail, Meal, Reliability, Cooking, Pressure, Vanilla, Global marketing, Multimedia, Senior, Ginger, Partnership, Collection, Snoring, Spice, Convenience food, Fast food, HelloFresh, Kindle, Tinder

HelloFresh , the world’s leading meal kit company, and Tinder , the world’s most popular app for meeting new people, are introducing a new relationship phase, Forking Season.

Key Points: 
  • HelloFresh , the world’s leading meal kit company, and Tinder , the world’s most popular app for meeting new people, are introducing a new relationship phase, Forking Season.
  • View the full release here: https://www.businesswire.com/news/home/20231106633349/en/
    HelloFresh and Tinder's Date Night Delight recipe series and Forking Seasonings.
  • (Photo: Business Wire)
    Ahead of the annual surge in Cuffing Season couplings, with over half (51%) of surveyed singles looking for a match this fall,2 HelloFresh and Tinder have teamed up to help new couples with an exclusive Date Night Delights recipe series.
  • 1 HelloFresh x Tinder Forking Season Survey, October 2023
    2 HelloFresh Valentine’s Day Survey, February 2022

DeRUCCI Launches First AIoT Smart Mattress

Retrieved on: 
星期三, 十一月 1, 2023
Technology, Men, Retail, Health, Consumer, Home Goods, Artificial Intelligence, Other Technology, Other Retail, IOT (Internet of Things), General Health, Other Consumer, Specialty, Women, Internet of things, FIR, Peter Hancock (professor), Renni Rucci, Human, Temperature, BMI, Heart rate, Aromatherapy, Respiration, LaTeX, PSG, Artificial intelligence of things, Research, Exercise, Multimedia, Artificial intelligence, Sleep, Conditional sentence, Immunity, Thermoregulation, Diet, Polysomnography, Algorithm, T11, Safety, Snoring, AI, Police aviation in the United Kingdom, Tidal, Pharmaceutical industry, Medical device, Carbon fibers, Consumer electronics

The DeRUCCI Group https://www.derucci.com , a leading public company and sleep technology brand, launched today the DeRUCCI T11 Pro Smart Mattress, an Artificial Intelligence of Things (AIoT) intelligent sleep solution.

Key Points: 
  • The DeRUCCI Group https://www.derucci.com , a leading public company and sleep technology brand, launched today the DeRUCCI T11 Pro Smart Mattress, an Artificial Intelligence of Things (AIoT) intelligent sleep solution.
  • Based on extensive sleep/health research conducted by DeRUCCI with international universities and institutions, the DeRUCCI T11 Pro Smart Mattress is the first smart mattress that instantly adjusts to the individual’s health for optimal sleep; actually warning the user about potential health issues before they are aware of them.
  • The DeRUCCI smart mattress employs big data based on 1.08 billion pieces of sleep data, AI software algorithms, smart software/hardware adjustments, and sleep monitoring; and connects to other AIoT home appliances to control the bedroom’s smart thermostat, air conditioner, aromatherapy, air purifier, sleep-enhancing lighting, meditation products, sleep aids, and other IoT devices.
  • The DeRUCCI T11 Pro AIoT Smart Mattress is available immediately in China and in the U.S. in Q3 2024, priced at $8,250.

Tempur-Pedic Ranked #1 in Customer Satisfaction Among Mattresses Purchased Online in the J.D. Power 2023 Study

Retrieved on: 
星期四, 十一月 2, 2023
Online, TPX, Customer satisfaction, Tempur-Pedic, Chemical oxygen demand, NYSE, Research online, purchase offline, Gamer, TEMPUR, J.D. Power, Tempur Sealy International, Sleep, Snoring, Collection, Retail

LEXINGTON, Ky., Nov. 2, 2023 /PRNewswire/ -- Tempur Sealy International, Inc. (NYSE: TPX, "Company" or "Tempur Sealy"), the company synonymous with innovation in the mattress industry, today announced that its Tempur-Pedic® brand was awarded #1 in Customer Satisfaction for the Online Purchase segment in the J.D. Power 2023 U.S. Mattress Satisfaction Study*. This award marks the third-consecutive year that Tempur-Pedic has achieved this distinction in the Online Purchase category, and the brand has been recognized by J.D. Power for six of the previous seven years among mattresses purchased online and in-store.

Key Points: 
  • Power for six of the previous seven years among mattresses purchased online and in-store.
  • In addition to being ranked #1 in overall customer satisfaction, Tempur-Pedic scored highest in 5 factors in the Online Purchase category, which include support, durability, comfort, price, and warranty.
  • Power 2019-2022 Mattress Satisfaction Reports, which measures customer satisfaction with their in-store mattress purchase experience.
  • Power 2021-2023 U.S. Mattress Satisfaction Studies, which measures customers' satisfaction with their online mattress purchase experience.